The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
- PMID: 12406915
- DOI: 10.1182/blood-2002-06-1831
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
Abstract
In acute-type leukemia, no method for the prediction of relapse following allogeneic stem cell transplantation based on minimal residual disease (MRD) levels is established yet. In the present study, MRD in 72 cases of allogeneic transplantation for acute myeloid leukemia, acute lymphoid leukemia, and chronic myeloid leukemia (accelerated phase or blast crisis) was monitored frequently by quantitating the transcript of WT1 gene, a "panleukemic MRD marker," using reverse transcriptase-polymerase chain reaction. Based on the negativity of expression of chimeric genes, the background level of WT1 transcripts in bone marrow following allogeneic transplantation was significantly decreased compared with the level in healthy volunteers. The probability of relapse occurring within 40 days significantly increased step-by-step according to the increase in WT1 expression level (100% for 1.0 x 10(-2)-5.0 x 10(-2), 44.4% for 4.0 x 10(-3)-1.0 x 10(-2), 10.2% for 4.0 x 10(-4)-4.0 x 10(-3), and 0.8% for < 4.0 x 10(-4)) when WT1 level in K562 was defined as 1.0). WT1 levels in patients having relapse increased exponentially with a constant doubling time. The doubling time of the WT1 level in patients for whom the discontinuation of immunosuppressive agents or donor leukocyte infusion was effective was significantly longer than that for patients in whom it was not (P <.05). No patients with a short doubling time of WT1 transcripts (< 13 days) responded to these immunomodulation therapies. These findings strongly suggest that the WT1 assay is very useful for the prediction and management of relapse following allogeneic stem cell transplantation regardless of the presence of chimeric gene markers.
Comment in
-
Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.Blood. 2003 Jul 15;102(2):773-4; author reply 774. doi: 10.1182/blood-2003-03-0980. Blood. 2003. PMID: 12835231 No abstract available.
Similar articles
-
Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.Blood. 2003 Jul 15;102(2):773-4; author reply 774. doi: 10.1182/blood-2003-03-0980. Blood. 2003. PMID: 12835231 No abstract available.
-
WT1 gene transcript assay for relapse in acute leukemia after transplantation.Leuk Lymphoma. 2004 Sep;45(9):1747-53. doi: 10.1080/10428190410001687503. Leuk Lymphoma. 2004. PMID: 15223632 Review.
-
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.Clin Transplant. 2011 Mar-Apr;25(2):308-16. doi: 10.1111/j.1399-0012.2010.01251.x. Clin Transplant. 2011. PMID: 20412098
-
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.Bone Marrow Transplant. 2004 Jan;33(1):47-52. doi: 10.1038/sj.bmt.1704296. Bone Marrow Transplant. 2004. PMID: 14704656
-
Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia.Leuk Lymphoma. 1998 Jun;30(1-2):55-61. doi: 10.3109/10428199809050929. Leuk Lymphoma. 1998. PMID: 9669676 Review.
Cited by
-
Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Leuk Lymphoma. 2013 Nov;54(11):2490-9. doi: 10.3109/10428194.2013.783910. Epub 2013 Apr 30. Leuk Lymphoma. 2013. PMID: 23480492 Free PMC article.
-
Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.J Med Life. 2012 Oct-Dec;5(Spec Issue):36-43. J Med Life. 2012. PMID: 31803284 Free PMC article.
-
Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.Biomed Res Int. 2014;2014:123079. doi: 10.1155/2014/123079. Epub 2014 Aug 17. Biomed Res Int. 2014. PMID: 25202702 Free PMC article.
-
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Semin Immunol. 2010 Jun;22(3):162-72. doi: 10.1016/j.smim.2010.02.003. Epub 2010 May 26. Semin Immunol. 2010. PMID: 20537908 Free PMC article. Review.
-
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9. doi: 10.1073/pnas.1008051107. Epub 2010 Jul 14. Proc Natl Acad Sci U S A. 2010. PMID: 20631300 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials